What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

Abstract

In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.